格列美脲(98例)与格列本脲(87例)治疗2型糖尿病的比较

目的 :比较格列美脲与格列本脲治疗 2型糖尿病的临床疗效。方法 :2型糖尿病病人 185例 ,随机分为 2组。格列美脲组 98例 ,男性 5 2例 ,女性4 6例 ,年龄 (5 2±s 8)a ,予格列美脲 ,po ,剂量范围1～ 8mg·d- 1;格列本脲组 87例 ,男性 4 6例 ,女性4 1例 ,年龄 (5 2± 9)a ,予格列本脲 ,po ,剂量范围2 .5～ 15mg·d- 1;疗程均为 10wk。观察 2组血糖、胰岛素、C肽等的变化及不良反应。结果 :2组均具有良好的降空腹血糖、餐后 2h血糖及糖化血红蛋白作用 ,对空腹胰岛素、C肽水平影响 2组无差异。治疗 10wk末 2组餐后 2h胰岛素和C肽水平均升高 ,升高程度格列美脲组低于格列本脲组 (P <0 .0 1) ,低血糖反应发生率格列美脲组 (15 % )低于格列本脲组 (31% ) ,且不增加病人体重。结论 :格列美脲和格列本脲治疗 2型糖尿病疗效均良好 ,格列美脲不良反应少。

Glimepiride (98 patients) vs glibenclemide (87 patients) in treatment of type 2 diabetes

AIM: To observe the clinical effect of glimepiride in the treatment of type 2 diabetes. METHODS: One hundred and eighty five patients with type 2 diabetic were randomly divided into two groups. Glimepiride group of 98 patients (M 52, F 46; age (52± s 8) a) was treated with glimepiride 1～8 mg·d -1 , po , for 10 wk. Glibenclamide group of 87 patients (M 46, F 41; age (52±9) a) was treated with glibenclamide 2.5～15 mg·d -1 , po , for 10 wk. The changes of blood glucose, insulin, C peptide and adverse reaction in two groups were observed. RESULTS: Similar decrease of infasting blood glucose, 2 h postprandial blood glucose and HbA1c was showed in the two groups. There was no difference on the fasting serum insulin and C peptide between the two groups. After 10 wk treatment, both postprandial serum insulin and C peptide were higher than that before the treatment in two groups. But glimepiride group had less effect on increasing 2 h postprandial serum insulin and C peptide level than that of glibenclamide group ( P <0.01)。 There was a lower incidence of hypoglycemia in glimepiride group than that in glibenclamide group (15 % vs 31 %, P < 0.05). And glimepiride group didn't increase the weight. CONCLUSION: Glimepiride has a favorable effect in the treatment of type 2 diabetes with few adverse reactions.